QSC RESEARCH GRADE
≥99% HPLC PurityMS ConfirmedJanoshik COA5-Region Domestic ShippingExtended Half-Life
What is IGF-1 LR3 0.1mg?
IGF-1 LR3 (Long R3 IGF-1) is a synthetic analog of Insulin-like Growth Factor 1 with an arginine substitution at position 3 and an N-terminal 13-amino acid extension that dramatically reduces IGF-binding protein (IGFBP) affinity — extending plasma half-life from ~12 minutes (native IGF-1) to ~20-30 hours. Activates IGF-1R (IGF-1 receptor) promoting glucose uptake, protein synthesis, anti-apoptosis, and myogenic differentiation. The 0.1mg/vial format provides a micro-dose format for dose-finding, in vitro cell culture research, and low-dose receptor binding studies.
Research Applications
Myogenesis & Muscle Cell Research
IGF-1R activation drives myogenic differentiation (MyoD, myogenin expression), protein synthesis (mTOR/S6K pathway), and satellite cell activation. 0.1mg format for in vitro C2C12 myoblast research.
IGFBP Interaction Studies
LR3 modification reduces IGFBP-3 affinity — enables comparison of IGFBP-bound vs free IGF-1 bioavailability. Ligand competition assays.
Dose-Finding & Receptor Pharmacology
0.1mg/vial suits low-concentration in vitro dose-response curves and EC50 determination for IGF-1R pharmacology.
Quick Specs
| Product | IGF-1 LR3 0.1mg × 10 Vials (1mg total) |
| Sequence | IGF-1 with N-terminal extension and Arg³ substitution |
| Format | Lyophilised powder, 10-vial kit |
| Purity | ≥99% HPLC, MS confirmed |
| Half-Life | ~20-30 hours (vs ~12 min native IGF-1) |
| Storage | −20°C lyophilised; 4°C reconstituted, 7 days |
